BioVector? CHLA-20 人神經(jīng)母細(xì)胞瘤細(xì)胞系 / BioVector? CHLA-20 Human Neuroblastoma Cell Line

通用定義 / General Definition:

BioVector? CHLA-20 是一種源自人類神經(jīng)母細(xì)胞瘤 (Neuroblastoma) 的細(xì)胞系。該細(xì)胞系與 CHLA-15 類似，同樣建立于一名經(jīng)歷過密集化療后復(fù)發(fā)的患兒。然而，CHLA-20 在分子表型上具有獨(dú)特性：它通常被鑒定為 MYCN 非擴(kuò)增型 (MYCN Non-amplified)，但可能存在其他遺傳學(xué)改變（如 1p 缺失或 ALK 突變/擴(kuò)增）。該細(xì)胞系是研究復(fù)發(fā)性、難治性神經(jīng)母細(xì)胞瘤中非 MYCN 驅(qū)動(dòng)因素的關(guān)鍵模型，常用于篩選新型化療組合以及針對神經(jīng)嵴起源腫瘤的靶向治療研究。

BioVector? CHLA-20 is a human cell line derived from Neuroblastoma. Similar to CHLA-15, it was established from a pediatric patient at the time of disease relapse following heavy prior therapy. However, CHLA-20 is molecularly distinct, typically characterized as MYCN Non-amplified, though it may harbor other genetic aberrations such as 1p deletion or ALK mutations/amplification. This cell line serves as a critical model for studying non-MYCN drivers in recurrent, refractory neuroblastoma and is frequently used for screening novel drug combinations and targeted therapies against tumors of neural crest origin.

BioVector? CHLA-20 技術(shù)說明書 (Technical Datasheet)

中文版說明書 (Chinese Datasheet)

1. 產(chǎn)品基本信息

• 產(chǎn)品名稱： BioVector? CHLA-20 人神經(jīng)母細(xì)胞瘤細(xì)胞

• 組織來源： 轉(zhuǎn)移灶（通常為外周血、骨髓或復(fù)發(fā)腫塊）

• 分子特征：MYCN 單拷貝（非擴(kuò)增）；可能攜帶 TP53 突變或 ALK 相關(guān)改變。

• 生長特性： 貼壁生長。

• 細(xì)胞形態(tài)： 上皮樣或成纖維細(xì)胞樣，具有明顯的雙極或多極神經(jīng)突觸樣延伸。

2. 培養(yǎng)條件

• 基礎(chǔ)培養(yǎng)基： BioVector? IMDM 或 DMEM/F-12 (1:1)。

• 血清添加： 10% - 20% BioVector? 優(yōu)質(zhì)胎牛血清 (FBS)。

• 補(bǔ)充因子： 為維持復(fù)發(fā)細(xì)胞的穩(wěn)健生長，建議添加非必需氨基酸 (NEAA) 和 L-谷氨酰胺。

• 培養(yǎng)環(huán)境： 37 攝氏度，5% $CO_2$。

• 傳代比例： 1:3 至 1:5；相比于 CHLA-15，CHLA-20 的倍增時(shí)間通常較短，生長更為迅速。

3. 細(xì)胞應(yīng)用

• 比較腫瘤學(xué)： 與 MYCN 擴(kuò)增型細(xì)胞對照，研究不同遺傳背景下的耐藥差異。

• ALK 抑制劑篩選： 若該亞型攜帶 ALK 突變，則是評估第二/三代 ALK 抑制劑效能的理想模型。

• 免疫療法研究： 用于研究 GD2 抗體或其他神經(jīng)母細(xì)胞瘤靶向免疫療法的細(xì)胞毒性實(shí)驗(yàn)。

4. 注意事項(xiàng)

• 匯合度控制： 建議在細(xì)胞達(dá)到 80% 匯合時(shí)傳代。過度生長會(huì)導(dǎo)致細(xì)胞堆疊成團(tuán)，不僅增加消化難度，還可能導(dǎo)致表型漂移。

• 消化參數(shù)： 該細(xì)胞對胰酶較為敏感，建議使用預(yù)溫的 0.25% Trypsin-EDTA 消化 2-3 分鐘，待細(xì)胞變圓后立即加入含血清培養(yǎng)基終止。

English Datasheet

1. General Product Information

• Product Name: BioVector? CHLA-20 Human Neuroblastoma Cell Line

• Source: Metastatic site (typically peripheral blood, bone marrow, or relapsed mass)

• Molecular Profile:MYCN Non-amplified (Single copy); potentially carries TP53 mutations or ALK-related alterations.

• Growth Properties: Adherent.

• Morphology: Epithelial-like or fibroblast-like; cells often display distinct bipolar or multipolar neurite extensions.

2. Culture Conditions

• Basal Medium: BioVector? IMDM or DMEM/F-12 (1:1).

• Serum Supplement: 10% - 20% BioVector? Fetal Bovine Serum (FBS).

• Supplements: Supplementation with Non-Essential Amino Acids (NEAA) and L-Glutamine is recommended to support robust growth of this relapse-derived line.

• Incubation: 37°C, 5% $CO_2$.

• Subculturing: 1:3 to 1:5 ratio; CHLA-20 typically exhibits faster doubling times compared to CHLA-15.

3. Applications

• Comparative Oncology: Serving as a non-amplified control to study resistance mechanisms across different genetic backgrounds.

• ALK Inhibitor Screening: An ideal model for evaluating the efficacy of next-generation ALK inhibitors if the specific sub-clone harbors ALK aberrations.

• Immunotherapy Assays: Utilized in cytotoxicity experiments for GD2 antibodies or other neuroblastoma-targeted immunotherapies.

4. Key Usage Notes

• Confluency Management: Maintain cultures in the exponential growth phase; subculture at ~80% confluency to prevent excessive cell-to-cell stacking and subsequent phenotypic drift.

• Dissociation Sensitivity: These cells are relatively sensitive to enzymatic dissociation. Use pre-warmed 0.25% Trypsin-EDTA for 2-3 minutes and neutralize immediately once cells appear rounded to preserve viability.

注意 / Note: BioVector? CHLA-20 應(yīng)在生物安全二級(jí) (BSL-2) 條件下操作。由于其源自復(fù)發(fā)性樣本，細(xì)胞可能表現(xiàn)出較高的代謝異質(zhì)性，建議在進(jìn)行藥物篩選前進(jìn)行 STR 鑒定以確保細(xì)胞系純度。

BioVector? CHLA-20 should be handled under Biosafety Level 2 (BSL-2) conditions. Given its origin from a relapsed clinical specimen, the line may exhibit metabolic heterogeneity; BioVector? recommends STR profiling to verify cell line identity before major drug screening assays.

BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號(hào):1843439339

網(wǎng)址

http://www.nedfriskphoto.com